ZDA
PBYI icon

Zweig-DiMenna Associates’s Puma Biotechnology PBYI Stock Holding History

Zweig-DiMenna Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-44,355
Closed -$10.6M – 311
2014
Q3 		$10.6M Buy
+44,355
New +$9.11M 0.46% 74

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Zweig-DiMenna Associates's PBYI Position: Q4 2014 in Review

Zweig-DiMenna Associates sold out of Puma Biotechnology (PBYI) in Q4 2014, closing a stake of 44,355 shares — an estimated $10.6M sold.

Zweig-DiMenna Associates first reported a position in PBYI in Q3 2014 and held it in 1 quarter. The position peaked at $10.6M in Q3 2014. 189 funds tracked by Wall St. Rank hold PBYI as of Q4 2014.

  • Zweig-DiMenna Associates reported no remaining Puma Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 44,355 Puma Biotechnology shares in Q4 2014, an estimated $10.6M.
  • Zweig-DiMenna Associates first reported a position in Puma Biotechnology in Q3 2014 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Puma Biotechnology position peaked at $10.6M in Q3 2014.
  • 189 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2014, filed 12 Feb 2015.